Dr. Mert Sabuncu

Weill Cornell Medicine has received a projected $4 million grant from the National Cancer Institute, part of the National Institutes of Health, to conduct a clinical trial testing whether a new imaging approach could reduce the need for biopsies to monitor prostate cancer.

A new AI-based system for analyzing images taken over time can accurately detect changes and predict outcomes, according to a study led by investigators at Weill Cornell Medicine, Cornell’s Ithaca campus and Cornell Tech.